Regeneron (REGN +2.71%), a leading biotechnology firm known for its work in immunology and ophthalmology, reported Q2 2025 earnings on August 1, 2025. The headline news: the company posted Non-GAAP earnings per share of $12.89, towering nearly 52.9% above the non-GAAP consensus estimate of $8.43. Reported GAAP revenue hit $3.68 billion, also ahead of the projected $3.29 billion (GAAP), and up 3.6% year-over-year. This performance was set against ongoing manufacturing and regulatory hurdles, particularly in its retinal disease portfolio, but momentum from collaboration and immunology therapies continued to drive results. Overall, the quarter reflected financial strength and operational discipline, though some key segments faced headwinds.
| Metric | Q2 2025 | Q2 2025 Estimate | Q2 2024 | Y/Y Change |
|---|---|---|---|---|
| EPS (Non-GAAP) | $12.89 | $8.43 | $11.56 | 11.5% |
| Revenue (GAAP) | $3.68 billion | N/A | $3.55 billion | 3.7% |
| GAAP Net Income | $1.39 billion | $1.43 billion | -2.8% | |
| Non-GAAP Net Income | $1.42 billion | $1.35 billion | 5.2% | |
| Gross Margin on Net Product Sales (Non-GAAP) | 86% | 89% | (3) pp |
Source: Analyst estimates for the quarter provided by FactSet.
Company overview and strategic focus
Regeneron develops, manufactures, and markets medicines for serious diseases with a primary focus on immunology, ophthalmology, oncology, and rare conditions. Its scientific model centers on a robust pipeline, powered by technologies that accelerate the creation of new treatments for conditions with unmet medical needs.
The company relies heavily on research and development (R&D) and on strategic partnerships, especially with Sanofi and Bayer. These relationships allow it to share costs and risks while expanding access to global markets. Key to Regeneron’s success is balancing investment in innovation with the need to maintain strong financial performance. The company’s ability to navigate regulatory scrutiny and manufacturing challenges is increasingly important, particularly given industry-wide changes following the COVID-19 pandemic.
Quarterly highlights: Financial and operational performance
Regeneron’s Q2 2025 results stood out with a significant beat on both non-GAAP earnings and GAAP revenue. Non-GAAP earnings per share jumped 11.5% year-over-year. GAAP revenue edged up 4% year-over-year, driven by growth in collaboration income and high-margin products. Operational leverage was evident: although U.S. net product sales dipped—mainly due to ongoing challenges for the EYLEA franchise—collaboration revenues more than offset these declines. The company’s collaboration with Sanofi (Dupixent, an immunology biologic drug) yielded a 29.7% increase in collaboration revenue versus Q2 2024, with Regeneron’s share of Dupixent profits rising 30% to $1.28 billion. Libtayo, an oncology immunotherapy, delivered global net product sales up 27%.
Gross margin on net product sales fell to 86% on a Non-GAAP basis, down 4 percentage points compared to Q2 2024, mainly due to higher manufacturing investment and inventory write-offs driven by more complex product launches and upgrades at external manufacturing suppliers. Despite margin compression, the company maintained disciplined control over selling, general, and administrative expenses, which decreased 19% Non-GAAP. Research and development spending grew 20% (non-GAAP), reflecting stepped-up investment in the late-stage and mid-stage clinical pipeline—cited by management as vital for future growth. The quarter also saw strong capital allocation, with over $2.3 billion returned to shareholders through buybacks and a newly instituted dividend.
The EYLEA HD product—an ophthalmology treatment for various eye diseases—showed a 29% sales increase in the U.S, but this was more than offset by a sharp decline in legacy EYLEA revenue, largely linked to market share losses, patient affordability issues, and shifting insurance reimbursement trends. The combined EYLEA HD + EYLEA franchise’s U.S. sales slid 25%. On the other end, Dupixent continued its rapid expansion, benefiting from new indications and broader international adoption. Oncology segment progress included the U.S. Food and Drug Administration (FDA) approval for Lynozyfic (multiple myeloma treatment) and strong data supporting further approvals for Libtayo in skin cancer.
A major theme in the quarter was external regulatory and manufacturing disruption. Approvals for EYLEA HD enhancements and other pipeline products with PDUFA dates in August 2025 have been delayed due to inspection findings at the Catalent Indiana plant, a third-party supplier recently acquired by Novo Nordisk A/S. Regeneron cited “increased scrutiny by the FDA post-COVID on contract manufacturers” as the core cause of these delays. While management emphasized that the anticipated regulatory hurdles are expected to be resolved quickly, the timeline remains contingent on external parties’ compliance. These delays not only affect the timing of product commercialization but could also potentially impact market share and future revenue ramp.
Competitive headwinds were acutely felt within U.S. ophthalmology. The EYLEA franchise faced significant erosion, with legacy EYLEA U.S. net product sales down 39% compared to Q2 2024, as more patients and physicians shifted to lower-cost compounded alternatives such as repackaged Avastin (bevacizumab). This was amplified by the winding down of co-pay support foundations and broader affordability issues within the Medicare population. In response, Regeneron committed $200 million in matching funds through the end of 2025 to re-establish patient assistance and called on industry peers to contribute, though long-term resolution will depend on systemic policy changes.
The immunology and oncology segments provided a sharp contrast to ophthalmology. Dupixent, an injectable therapy for several inflammatory diseases, recorded global net sales of $4.34 billion (up 22%), with two new FDA-approved disease indications. Libtayo, used to treat some advanced cancers, also grew market share sharply, driven by both U.S. and international sales.
There were no material one-time events or new trend-based dividend changes in the period, but the company’s cash deployment was robust. It repurchased $1.07 billion in shares and maintained a sizable liquidity position ($17.5 billion in cash and marketable securities at June 30, 2025).
Looking ahead: Management commentary and outlook
For fiscal 2025, management updated select Non-GAAP guidance items, including an increase in R&D expense to $5.10–$5.20 billion and lower selling, general, and administrative cost expectations. The Non-GAAP gross margin target was set at 86% for fiscal 2025. While no formal revenue or earnings-per-share guidance was provided, management signaled confidence in continued trends for collaboration income, Dupixent growth, and further pipeline progress.
Key risks highlighted by leadership remain centered around external regulatory and manufacturing variables, continued pressure on the ophthalmology business, and rising competition across therapy areas. Investors are advised to keep a close watch on the timing and resolution of FDA-related issues at contract manufacturing sites, the rate of decline in U.S. ophthalmology sales, and the ongoing expansion of the immunology franchise. Management remains focused on executing its innovation agenda and re-investing cash into pipeline and strategic business development.
Regeneron does not currently pay a dividend.
Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted.
